Efavirenz treatment improves retinal vaso-obliteration and pathological neovascularization in a mouse model of retinopathy of prematurity
The current study demonstrates the developmental regulation of CYP46A1 and the dysregulated expression and levels of the downstream metabolite 24-Hydroxycholesterol (24HC) in OIR mice. The study further suggests that EFV treatment (in part via CYP46A1 activation) may improve key pathological features associated with pathological neovascularization in OIR mice.
Authors
- Menaka C. Thounaojam (ORCID: https://orcid.org/0000-0002-3422-2053)
- Shubhra Rajpurohit
- Pamela M. Martin (ORCID: https://orcid.org/0000-0001-6278-4953)
- Ravirajsinh N. Jadeja (ORCID: https://orcid.org/0000-0002-1712-454X)
- Josephine Rudd Zhong Manis
- Allston Oxenrider
- Briah Bailey
- Gayatri Seth
Institutions
- Meharry Medical College (US)
- Augusta University (US)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-02-23
- DOI
- https://doi.org/10.3389/fmed.2026.1745351
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00